Latanoprostene Bunod
FDA-approved product (solution/drops, ophthalmic), marketed as Latanoprostene Bunod, Vyzulta.
- Registered studies
- 9
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Glaucoma
- Ocular hypertension
- Open-angle glaucoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Prostaglandin analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae25.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
9registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Latanoprostene Bunod with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension
NCT04140279 · start 2022-05-13
Registered record
- Registry ID
- NCT04140279
- Conditions
- Ocular Hypertension
- Interventions
- Latanoprostene Bunod; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Withdrawn
- Start
- 2022-05-13
- Completion
- 2023-08
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOcular HypertensionInterventionLatanoprostene Bunod; PlaceboPhasePhase 4Registry statusWithdrawnNailfold Capillary Blood Flow With Latanoprost Bunod
NCT03949244 · start 2019-08-15
Registered record
- Registry ID
- NCT03949244
- Conditions
- Glaucoma, Open-Angle
- Interventions
- Latanoprost 0.005%; Latanoprost bunod 0.024%; Normal saline 0.9%; Nailfold capillaroscopy
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2019-08-15
- Completion
- 2020-10-01
- Enrolment
- 47
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma, Open-AngleInterventionLatanoprost 0.005%; Latanoprost bunod 0.024%; Normal saline 0.9%; Nailfold capillaroscopyPhasePhase 4Registry statusCompletedStudy Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity
NCT03931317 · start 2018-12-03
Registered record
- Registry ID
- NCT03931317
- Conditions
- OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension
- Interventions
- Latanoprostene bunod 0.024% QD; Timolol maleate 0.5% BID
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2018-12-03
- Completion
- 2023-03-01
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOAG - Open-Angle Glaucoma; OHT - Ocular HypertensionInterventionLatanoprostene bunod 0.024% QD; Timolol maleate 0.5% BIDPhaseNot applicableRegistry statusCompletedLong-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
NCT01895972 · start 2013-07-05
Registered record
- Registry ID
- NCT01895972
- Conditions
- Glaucoma; Ocular Hypertension
- Interventions
- Latanoprostene bunod
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-07-05
- Completion
- 2015-04-14
- Enrolment
- 130
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma; Ocular HypertensionInterventionLatanoprostene bunodPhasePhase 3Registry statusCompletedEfficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
NCT01895985 · start 2013-07
Registered record
- Registry ID
- NCT01895985
- Conditions
- Intraocular Pressure
- Interventions
- Latanoprostene bunod
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-07
- Completion
- 2013-10
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntraocular PressureInterventionLatanoprostene bunodPhasePhase 1Registry statusCompletedComparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01749904 · start 2013-01-31
Registered record
- Registry ID
- NCT01749904
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- BOL-303259-X; Timolol; BOL-303259-X
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-01-31
- Completion
- 2015-09-30
- Enrolment
- 420
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventionBOL-303259-X; Timolol; BOL-303259-XPhasePhase 3Registry statusCompletedComparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01749930 · start 2013-01
Registered record
- Registry ID
- NCT01749930
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- BOL-303259-X; Timolol; BOL-303259-X
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2015-05
- Enrolment
- 420
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventionBOL-303259-X; Timolol; BOL-303259-XPhasePhase 3Registry statusCompletedBOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01707381 · start 2012-11
Registered record
- Registry ID
- NCT01707381
- Conditions
- Ocular Hypertension; Open Angle Glaucoma
- Interventions
- BOL-303259-X; Timolol maleate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-11
- Completion
- 2014-02
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOcular Hypertension; Open Angle GlaucomaInterventionBOL-303259-X; Timolol maleatePhasePhase 2Registry statusCompletedStudy Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
NCT01223378 · start 2010-12-13
Registered record
- Registry ID
- NCT01223378
- Conditions
- Intraocular Pressure
- Interventions
- BOL-303259-X; Latanoprost
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-12-13
- Completion
- 2012-06-22
- Enrolment
- 413
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntraocular PressureInterventionBOL-303259-X; LatanoprostPhasePhase 2Registry statusCompleted